Navigation Links
Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
Date:11/15/2007

COGENT Trials To Enroll 4,000 Patients Worldwide

MENLO PARK, Calif., Nov. 15 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. announced today it is launching a global Phase III clinical program to evaluate the efficacy and safety of its novel combination therapy CGT-2168. The program, which includes the COGENT-1 and COGENT-2 trials, will enroll over 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

CGT-2168 is a unique once-daily pill that combines the antiplatelet agent clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole). The product is designed to significantly reduce the gastrointestinal side effects commonly associated with antiplatelet therapy.

COGENT stands for the Clopidogrel and the Optimization of Gastrointestinal Events Trial. The COGENT trials are designed to measure the incidence of upper gastrointestinal bleeding and ulcers in patients who take CGT-2168 and aspirin compared with patients who take clopidogrel and aspirin. The vast majority of patients who take clopidogrel also take aspirin.

Antiplatelet therapy is an integral part of treating patients with cardiovascular disease, including acute coronary syndrome, and has been shown to be effective in preventing major cardiovascular events. However, treatment with antiplatelet medicines such as clopidogrel, aspirin or the frequent combination of the two is associated with gastrointestinal bleeding, which in some cases can require hospitalization and even result in death.

"The benefits of antiplatelet therapy are well established, but the risk of bleeding associated with these treatments has been greatly under-appreciated," said Kim Fox, M.D., F.R.C.P., Director of Cardiology at Royal Brompton Hospital and Professor of Clinical Cardiology at Imperial College. "The gastrointestinal toxicity from dual antiplatelet therapy can result in patients skipping or stopping their treatment altogether," continued Dr. Fox. "Even a short discontinuation of therapy in patients who have recently had a drug eluting stent inserted can result in a heart attack. Clearly there is a need for a safer treatment option."

Recent clinical trial data documenting these side effects have begun focusing attention on the incidence and significance of bleeding associated with antiplatelet medicines.

"Our goal is to improve the safety and tolerability of antiplatelet therapy by significantly reducing gastrointestinal adverse events, including bleeding, to help patients stay on their intended antiplatelet treatment," said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Cogentus Pharmaceuticals. "We believe CGT-2168 may be a significant advance that will preserve and extend the cardiovascular benefits of antiplatelet therapy."

Phase III trials are the last stage of clinical testing required by the U.S. Food and Drug Administration. Successful Phase III studies allow a company to file a New Drug Application with the FDA for approval to market a new medicine.

Physicians and patients interested in obtaining more information about COGENT should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... on Tuesday, August 8, 2017.  Members of its senior management team ... markets open at 8:30 a.m. ET. The dial-in ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. Please ... A replay of the call ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released ... abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle ... how she has risen above. , In “Memories,” readers get a firsthand look at ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot as ... 100,000 children in their treatment program. Clubfoot is a pervasive problem in the ... is limited or non-existent. Without intervention, these children are destined to grow up ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical Quality Assurance:, Roles and ... 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , Early bird pricing for ... growing demands to track and report adverse events place even greater pressure on ...
Breaking Medicine News(10 mins):